Internal Medicine, Endocrinology, Diabetes, & Metabolism · Morris, IL
NPI
1497958201
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1367 N Division St
Morris, IL, 60450
Phone (815) 941-2007
Groups this clinician bills Medicare through
Medicare paid, 2024
$127K
2,598 services
Medicare patients, 2024
487
Average age 73
Drug cost, 2024
$3.3M
5,720 prescriptions
Company payments, 2025
$1,310
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Meiraj F Zuberi was code 99214 (office e&m - established), 1,002 times for 459 patients. In total Meiraj F Zuberi billed 2,598 services in 15 codes, and Medicare paid $127K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,002 | 459 | $90.05 | $90K |
| 82962 Clinical Chemistry | Office | 550 | 274 | $3.21 | $1,763 |
| 95251 Test - Miscellaneous | Office | 475 | 186 | $25.76 | $12K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 254 | 213 | $12.60 | $3,200 |
| 99211 Office E&M - Established | Office | 134 | 84 | $17.28 | $2,315 |
| 99204 Office E&M - New | Office | 77 | 77 | $123.30 | $9,494 |
| 95250 Test - Miscellaneous | Office | 56 | 37 | $103.28 | $5,784 |
| 99406 Behavioral Health Services | Office | 12 | 12 | $14.10 | $169 |
| 83036 Blood Count | Office | 12 | 11 | $9.52 | $114 |
By year: 2022 $147K for 2,493 services; 2023 $127K for 2,865 services; 2024 $127K for 2,598 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 550 | 274 | $3.21 | $1,763 |
| 83036 Blood Count | 12 | 11 | $9.52 | $114 |
Medicare prescription drug claims, 2024
In 2024, the drug Meiraj F Zuberi prescribed most often to Medicare patients was Ozempic (Semaglutide), with 919 prescriptions and refills. In total Meiraj F Zuberi wrote 5,720 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 919 | 1,507 | 180 | $1.4M |
| Levothyroxine Sodium Generic | 502 | 1,296 | 128 | $5,578 |
| Metformin Hcl Generic | 289 | 817 | 87 | $3,086 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 186 | 460 | 84 | $26K |
| Humalog Kwikpen U-100 Insulin Lispro | 183 | 373 | 60 | $73K |
| Synthroid Levothyroxine Sodium | 178 | 452 | 40 | $14K |
| Mounjaro Tirzepatide | 175 | 202 | 29 | $209K |
| Metformin Hcl Er Metformin Hcl | 166 | 458 | 58 | $1,494 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 153 | 333 | 47 | $19K |
| Glimepiride Generic | 153 | 414 | 42 | $1,247 |
| Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt | 149 | 283 | 33 | $246K |
| Tresiba Flextouch U-100 Insulin Degludec | 147 | 383 | 48 | $97K |
| Novolog Flexpen Insulin Aspart | 122 | 237 | 40 | $49K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 119 | 274 | 33 | $72K |
| Novolog Insulin Aspart | 115 | 192 | 26 | $30K |
Brand drugs: 3,246 claims; generic drugs: 1,890 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Meiraj F Zuberi $1,310 ($1,310 in general payments such as food, travel and fees) from 30 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $192.
| Company | Payments | Amount |
|---|---|---|
| Ascendis Pharma Endocrinology Inc ASND | 5 | $192 |
| Neurocrine BioSciences, Inc. NBIX | 5 | $139 |
| Tandem Diabetes Care, Inc. TNDM | 5 | $92.89 |
| Medtronic, Inc. MDT | 1 | $78.05 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $72.67 |
| Abbvie Inc. ABBV | 3 | $59.49 |
| Ascensia Diabetes Care Us Inc. | 3 | $55.56 |
| Phathom Pharmaceuticals, Inc. PHAT | 2 | $50.17 |
| Xeris Pharmaceuticals, Inc. | 3 | $49.85 |
| Radius Health, Inc. | 2 | $45.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.